Compare Huntington Bancshares Incorporated (HBAN) vs Viatris Inc (VTRS) Price & Performance

Huntington Bancshares (HBAN) trades at $15.37, up 1.32% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with Q3 2026 results pending. Revenue grew to $8.13B in 2025, and the stock trades at a P/E of 11.82, below the industry average. Recent news highlights increased call option activity and a dividend declaration of $0.16 payable in October 2026.

HBAN offers value with a low P/E and strong net income margin of 24.77%, but faces headwinds from interest rate pressures and reduced 2027 earnings guidance. Analyst consensus is a Buy with a $19.60 price target, implying 27% upside, though technical indicators and recent institutional put buying suggest near-term caution. Key risks include margin compression and competitive lending pressures.

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.